



## Resolution n° 5-2022-e

### **Cost Extension for the Project: ‘Increasing Market and Public Health Outcomes through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB’ (IMPAACT4TB)**

Recalling Unitaid Executive Board Resolution no. 14-2017-e of 31 August 2017, in which the Board approved the commitment of up to US\$ 58,887,058 for the project entitled “Increasing Market and Public Health Outcomes through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB” (the “Project”), to be implemented by The Aurum Institute NPC for a four-year period;

Noting that, in 2021, the Secretariat approved a twelve-month no-cost extension to funding for the Project ending on 31 August 2022;

Taking into account the assessment by the PRC and the Secretariat’s recommendations, the Board authorizes, subject to the availability of funds, the Executive Director to commit an additional amount of up to US\$ 19,170,752 for a twenty-eight-month extension of the Project.

The additional funding and extension to the Project duration shall not apply to the COVID-19 related Output and is conditional upon signature of a formal amendment to the grant agreement for the Project.

Marisol Touraine  
Chair of the Unitaid Executive Board

Date: 20 April 2022